Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
O14595
UPID:
CTDS2_HUMAN
Alternative names:
Nuclear LIM interactor-interacting factor 2; Protein OS-4; Small C-terminal domain phosphatase 2; Small CTD phosphatase 2
Alternative UPACC:
O14595; A8K5H4; Q53ZR2; Q6NZY3; Q9UEX1
Background:
Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 2, also known as Small CTD phosphatase 2, plays a crucial role in the regulation of RNA polymerase II transcription. It achieves this by preferentially catalyzing the dephosphorylation of 'Ser-5' within the C-terminal domain of POLR2A, impacting the transition from initiation to elongation of transcript synthesis. Additionally, it is involved in neuronal gene silencing in non-neuronal cells through recruitment by REST to genes with RE-1 elements.
Therapeutic significance:
Understanding the role of Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 2 could open doors to potential therapeutic strategies.